Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Novartis
SWOG Cancer Research Network
Medical College of Wisconsin
Novartis
Gruppo Italiano Malattie EMatologiche dell'Adulto
Ascentage Pharma Group Inc.
Masaryk University
UNC Lineberger Comprehensive Cancer Center
Milton S. Hershey Medical Center
Shenzhen Second People's Hospital
Gruppo Italiano Malattie EMatologiche dell'Adulto
Takeda
Novartis
Novartis
Niguarda Hospital
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
M.D. Anderson Cancer Center
Hamad Medical Corporation
Cancer Trials Ireland
Seoul National University Hospital
Fred Hutchinson Cancer Center